Literature DB >> 17337109

Use of ultrasound pulses combined with Definity for targeted blood-brain barrier disruption: a feasibility study.

Nathan McDannold1, Natalia Vykhodtseva, Kullervo Hynynen.   

Abstract

We have developed a method to use low-intensity focused ultrasound pulses combined with an ultrasound contrast agent to produce temporary blood-brain barrier disruption (BBBD). This method could provide a means for the targeted delivery of drugs or imaging agents into the brain. In all our previous work, we used Optison as the ultrasound contrast agent. The purpose of this study was to test the feasibility of using the contrast agent Definity for BBBD. A total of 36 non-overlapping locations were sonicated through a craniotomy in experiments in the brains of nine rabbits (four locations per rabbit; ultrasound [US] frequency: 0.69 MHz; burst: 10 ms; pulse repetition frequency (PRF): 1 Hz; duration: 20 s). The peak negative pressure amplitude ranged from 0.2 to 1.5 MPa. An additional 11 locations were sonicated using Optison at pressure amplitude of 0.5 MPa. Definity and Optison dosages were the same as those used clinically for ultrasound imaging: 10 and 50 microl/kg, respectively. The probability for BBBD (determined using MRI contrast agent enhancement) as a function of pressure amplitude was similar to that found earlier with Optison. For both agents, the probability was estimated to be 50% at 0.4 MPa using probit regression. Histologic examination revealed small, isolated areas of extravasated erythrocytes in some locations. At 0.8 MPa and higher, these areas were sometimes accompanied by tiny (dimensions of 100 microm or less) regions of damaged brain parenchyma. The magnitude of the BBBD was larger with Optison than with Definity at 0.5 MPa (signal enhancement: 13.3% +/- 4.4% vs. 8.4% +/- 4.9%; p = 0.04). In addition, more areas with extravasated erythrocytes were observed with Optison (5.0 +/- 3.5 vs. 1.4 +/- 1.9 areas with extravasation in histology section with largest effect; p = 0.03). We concluded that BBBD is possible using Definity at the dosage of contrast agent and the acoustic parameters tested in this study. The probability for BBBD as a function of pressure amplitude and the type of acute tissue effects were similar to what has been observed using Optison. However, under the experimental conditions used in this study, Optison produced a larger effect for the same acoustic pressure amplitude.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17337109      PMCID: PMC2066193          DOI: 10.1016/j.ultrasmedbio.2006.10.004

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  26 in total

1.  Differences in definity and optison microbubble destruction rates at a similar mechanical index with different real-time perfusion systems.

Authors:  Carolin Sonne; Feng Xie; John Lof; Joseph Oberdorfer; Patrick Phillips; E Carr Everbach; Thomas R Porter
Journal:  J Am Soc Echocardiogr       Date:  2003-11       Impact factor: 5.251

Review 2.  Drug and gene delivery to the brain: the vascular route.

Authors:  William M Pardridge
Journal:  Neuron       Date:  2002-11-14       Impact factor: 17.173

3.  Bioeffects of myocardial contrast microbubble destruction by echocardiography.

Authors:  Shuyuan Chen; Martin H Kroll; Ralph V Shohet; Peter Frenkel; Susan A Mayer; Paul A Grayburn
Journal:  Echocardiography       Date:  2002-08       Impact factor: 1.724

4.  Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles.

Authors:  Nickolai Sheikov; Nathan McDannold; Natalia Vykhodtseva; Ferenc Jolesz; Kullervo Hynynen
Journal:  Ultrasound Med Biol       Date:  2004-07       Impact factor: 2.998

5.  Membrane damage thresholds for 1- to 10-MHz pulsed ultrasound exposure of phagocytic cells loaded with contrast agent gas bodies in vitro.

Authors:  Douglas L Miller; Chunyan Dou
Journal:  Ultrasound Med Biol       Date:  2004-07       Impact factor: 2.998

6.  Multiphoton imaging of ultrasound/Optison mediated cerebrovascular effects in vivo.

Authors:  Scott B Raymond; Jesse Skoch; Kullervo Hynynen; Brian J Bacskai
Journal:  J Cereb Blood Flow Metab       Date:  2006-05-10       Impact factor: 6.200

7.  Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors.

Authors:  N D Doolittle; M E Miner; W A Hall; T Siegal; E Jerome; E Osztie; L D McAllister; J S Bubalo; D F Kraemer; D Fortin; R Nixon; L L Muldoon; E A Neuwelt
Journal:  Cancer       Date:  2000-02-01       Impact factor: 6.860

8.  Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits.

Authors:  K Hynynen; N McDannold; N Vykhodtseva; F A Jolesz
Journal:  Radiology       Date:  2001-09       Impact factor: 11.105

9.  Impact of myocardial contrast echocardiography on vascular permeability: comparison of three different contrast agents.

Authors:  Peng Li; William F Armstrong; Douglas L Miller
Journal:  Ultrasound Med Biol       Date:  2004-01       Impact factor: 2.998

Review 10.  Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers.

Authors:  Christopher Guerin; Alessandro Olivi; Jon D Weingart; H Christopher Lawson; Henry Brem
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

View more
  62 in total

Review 1.  Ultrasound enhanced drug delivery to the brain and central nervous system.

Authors:  Meaghan A O'Reilly; Kullervo Hynynen
Journal:  Int J Hyperthermia       Date:  2012       Impact factor: 3.914

2.  Increasing of blood-tumor barrier permeability through paracellular pathway by low-frequency ultrasound irradiation in vitro.

Authors:  Lilin Fan; Yunhui Liu; Haoqiang Ying; Yixue Xue; Zhen Zhang; Ping Wang; Libo Liu; Hua Zhang
Journal:  J Mol Neurosci       Date:  2010-11-23       Impact factor: 3.444

3.  In vivo transcranial cavitation threshold detection during ultrasound-induced blood-brain barrier opening in mice.

Authors:  Yao-Sheng Tung; Fotios Vlachos; James J Choi; Thomas Deffieux; Kirsten Selert; Elisa E Konofagou
Journal:  Phys Med Biol       Date:  2010-09-29       Impact factor: 3.609

4.  Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption.

Authors:  Nathan McDannold; Natalia Vykhodtseva; Kullervo Hynynen
Journal:  Ultrasound Med Biol       Date:  2008-02-21       Impact factor: 2.998

5.  Blood-brain barrier disruption induced by focused ultrasound and circulating preformed microbubbles appears to be characterized by the mechanical index.

Authors:  Nathan McDannold; Natalia Vykhodtseva; Kullervo Hynynen
Journal:  Ultrasound Med Biol       Date:  2008-01-22       Impact factor: 2.998

Review 6.  Drug delivery across the blood-brain barrier using focused ultrasound.

Authors:  Alison Burgess; Kullervo Hynynen
Journal:  Expert Opin Drug Deliv       Date:  2014-03-20       Impact factor: 6.648

Review 7.  Evaluating the safety profile of focused ultrasound and microbubble-mediated treatments to increase blood-brain barrier permeability.

Authors:  Dallan McMahon; Charissa Poon; Kullervo Hynynen
Journal:  Expert Opin Drug Deliv       Date:  2019-01-29       Impact factor: 6.648

Review 8.  Magnetic resonance-guided focused ultrasound: a new technology for clinical neurosciences.

Authors:  Ferenc A Jolesz; Nathan J McDannold
Journal:  Neurol Clin       Date:  2013-11-08       Impact factor: 3.806

9.  Targeted drug delivery with focused ultrasound-induced blood-brain barrier opening using acoustically-activated nanodroplets.

Authors:  Cherry C Chen; Paul S Sheeran; Shih-Ying Wu; Oluyemi O Olumolade; Paul A Dayton; Elisa E Konofagou
Journal:  J Control Release       Date:  2013-10-02       Impact factor: 9.776

Review 10.  Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system.

Authors:  Muna Aryal; Costas D Arvanitis; Phillip M Alexander; Nathan McDannold
Journal:  Adv Drug Deliv Rev       Date:  2014-01-22       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.